drugset / Trial / NCT01548924
Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors
Phase 1
Terminated
13 enrolled
Spanish National Cancer Research Centre
Hospital Universitari de Bellvitge · collabHospital Universitario de Fuenlabrada · collabM.D. Anderson Cancer Center · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The investigators plan to study the determination of the dose and the combination of antiangiogenic effect of dovitinib and cytotoxic activity of weekly paclitaxel in different types of malignant tumors.
Timeline
- Start
- 2012-04
- Primary completion
- 2013-02
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dovitinib | Small molecule | 100 mg | Oral |
| Subject | Dovitinib | Small molecule | 200 mg | Oral |
| Subject | Dovitinib | Small molecule | 300 mg | Oral |
| Subject | Dovitinib | Small molecule | 400 mg | Oral |
| Subject | Dovitinib | Small molecule | 500 mg | Oral |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |